Speaker Profile
Ph.D., CEO and Co-Founder, Hepta
Biography
Hamed Amini is Co-Founder and CEO of Hepta, an AI-native liquid biopsy company building the diagnostic and data platform for chronic disease, beginning with MASH. Hepta decodes cell-free DNA methylation signals in blood to deliver tissue-level insight without biopsy, powered by LiquidTransformer, a transformer AI architecture purpose-built for liquid biopsy in chronic disease.
Hamed founded Hepta in 2022 after more than a decade at the forefront of genomics and diagnostics. He was a founding team member at GRAIL, where he led work across technology and product development and translational strategy, and played a pivotal role in developing and launching Galleri, GRAIL's flagship multi-cancer early detection test. Earlier, he was a scientist in Illumina's research division, working at the forefront of next-generation sequencing technologies.
He holds a Ph.D. in Biomedical Engineering from UCLA and a B.Sc. in Mechanical Engineering from Sharif University of Technology.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Daniel De Carvalho, University of Toronto
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Minetta Liu, Natera
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Eric Klein, GRAIL
• Sarah Moseley, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
• Paul Shi, Amgen
• Christopher Troll, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Paolo Di Domenico, Allelica
AI-Driven Metagenomic and Host RNA Profiling for Precision Diagnosis of Infections
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life
Overcoming Limits of Traditional cfDNA Assays Using Active Chromatin
• Diana Abdueva, Aqtual
Whole-genome methylome-based early cancer signal detection
• Sally Mackenzie, EpiMethyl Analytics
BrainSee Sees the Brain: FDA-Approved AI for Predicting Modifiable Risk of Developing Alzheimer’s Within Five Year
• Padideh Kamali-Zare, Darmiyan
